Ask AI
ASH 2025: Key Studies in Leukemias

CE / CME

Conference to Clinic Highlights From the 2025 ASH Annual Meeting: Key Studies in Leukemias

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: February 27, 2026

Expiration: August 26, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Okoniewski M, Gonzalez Lugo J, et al. Moving away from standard induction in newly diagnosed acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2025;45:e473646.
  2. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629.
  3. Cherry EM, Abbott D, Amaya M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5:5565-5573.
  4. Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6:3997-4005.
  5. Fathi A, Perl A, Fell G, et al. Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2025. Abstract 6.
  6. Grembecka J, He S, Shi A, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol. 2012;8:277-284.
  7. Uckelmann HJ, Kim SM, Wong EM, et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020;367:586-590.
  8. Heikamp EB. Henrich JA, Perner F, et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022;139:894-906.
  9. Jen WY, DiNardo C, Short N, et al. Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2025. Abstract 47.
  10. Wang ES, Montesinos, P, Foran J et al. Ziftomenib in relapsed or refractory NPM1-mutated AML. J Clin Oncol. 2025;43:3381-3390.
  11. Ziftomenib [prescribing information]. San Diego, CA: Kura Oncology, Inc; 2025.
  12. Wang ES, Issa GC, Erba HP, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 2024;25:1310-1324.
  13. Erba H, Wang ES, Fathi ET, Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b results from KOMET-007. Presented at: European Hematology Association 2025 Congress. Abstr S136.
  14. Issa G, Fathi A, Zeidan A, et al. Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: updated phase 1a/b safety and clinical activity results from KOMET-007. Blood. 2025;146(Supplement 1):764.
  15. Roboz G, Wang E, Fathi A, et al. Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: phase 1b results from KOMET-007. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2025. Abstract 766.
  16. Konopleva M, Thirman MJ, Pratz KW, et al. Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naïve acute myeloid leukemia. Clin Cancer Res. 2022;28:2744-2752.
  17. Short NJ, Daver N, Dinardo CD, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42:1499-1508.
  18. Altman J, Perl A, Wang E, et al. Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2025. Abstract 654.
  19. Gilteritinib [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; 2022.
  20. El Achi H, Dupont E, Paul S, et al. CD123 as a biomarker in hematolymphoid malignancies: principles of detection and targeted therapies. Cancers (Basel). 2020;12:3087.
  21. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777.
  22. Muñoz L, Nomdedéu, JF, López O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261-1269.
  23. Kovtun Y, Jones GE, Adams S, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2:848-858.
  24. Daver N, Montesinos P, Altman JK, et al. Pivekimab sunirine (PVEK, IMGN632), a CD123-targeting antibody-drug conjugate, in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia. Blood. 2023;142(Supplement 1):2906.
  25. Daver N, Advani, A, De La Fuente Burguera, A, et al. Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2025. Abstract 651.
  26. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315-2326.
  27. Asciminib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2025.
  28. Ernst T, Coutre P, Crysandt M, et al. Improved long-term tolerability and efficacy of asciminib-based combination therapies in newly diagnosed CML patients - the fascination trial. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2025. Abstract 903.
  29. Cortes J, Atallah E, Andorsky, D, et al. Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI). Presented at: 67th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2025. Abstract 906.